Join
Live feed
·
INSIDERFilingvia Quantisnow
Syros Pharmaceuticals Inc. logo

Director Simonian Nancy A converted options into 40,125 shares, increasing direct ownership by 30% to 175,783 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SYRS (Syros Pharmaceuticals Inc.) and more on Quantisnow.

Director Simonian Nancy A converted options into 40,125 shares, increasing direct ownership by 30% to 175,783 units (SEC Form 4) | Quantisnow